Development of novel therapeutics for patients with high-risk non-muscle-invasive bladder cancer is an important topic considering the rather limited options currently available.
Statement of Translational Relevance
Development of novel therapeutics for patients with high-risk non-muscle-invasive bladder cancer is an important topic considering the rather limited options currently available.
Microtubules are one of the most successful targets in cancer therapy to date and the recent Phase I trial of intravesical docetaxel for the treatment of non-muscle-invasive bladder cancer, refractory to Bacillus Calmette-Guérin (BCG) therapy, has shown this to be a promising intravesical agent. Treatment failure is thought to be in part due to the short dwelltime of intravesical drugs and low drug uptake in the bladder wall. Conventional formulations are typically maintained in the bladder for 2 h and urothelial drug exposure rarely lasts beyond the first voiding of urine after instillation. In this study, we developed a novel mucoadhesive controlled-release formulation of docetaxel. Mucoadhesive polymers have several advantages when compared to conventional drug carriers, including localization at the specific target site, prolonged residence time and increase drug uptake. Overall, our data show promising antitumor efficacy and safety in a recently validated orthotopic model of bladder cancer and provide a clear rationale for the intravesical use of this nanoparticulate formulation over the commercial formulation of docetaxel in the treatment of non-muscleinvasive bladder cancer.
Conclusions:
Our data show promising in vivo antitumor efficacy and provide preclinical proof-of-principle for the intravesical application of mucoadhesive nanoparticulate DTX formulation in the treatment of bladder cancer.
Introduction
Bladder cancer is a significant public health problem responsible for more than 130,000 deaths annually worldwide (1) . In the US, bladder cancer is the fourth most common cancer diagnosed in men, with an estimated 70,530 new cases and 14,680 deaths from the disease in 2010 (2) . Approximately 70-80% of patients with bladder cancer initially present with superficial disease that does not invade the muscularis propria (3) . Transurethral resection (TUR) is the primary treatment method for non-muscle-invasive or "superficial" carcinoma, which consists of the surgical removal of tumor nodules from the bladder wall (4, 5) .
However, there is a high rate of tumor recurrence and high chance of disease progression after TUR alone (6) . This is probably due to incomplete removal of the tumors and/or implantation of cancer cells in normal tissues of the bladder. Intravesical therapy, which involves instillation of one or more chemo-and/or immunotherapeutic agents into the bladder following resection, has become the standard of care for the treatment of non-muscleinvasive bladder cancers (7) . Systemic administration of anticancer drugs offers little therapeutic benefit in these patients, as the urothelial layer of the bladder is not vascularized (8) . By contrast, intravesical chemotherapy has the potential to selectively deliver high drug concentrations to tumor-bearing bladder tissues while minimizing the systemic exposure.
Immunotherapy with bacillus Calmette-Guérin (BCG) is the most effective form of intravesical therapy for prophylaxis of recurrence and progression in non-muscle-invasive bladder cancer patients (9) . However, it is associated with frequent local and/or systemic adverse effects including BCG sepsis (10, 11) . The incidence of local and systemic adverse effects is significantly lower with chemotherapeutic agents. However, the response to intravesical chemotherapy is incomplete and tumor recurrence is still high (up to 80%) in patients with non-muscle-invasive bladder cancer (12) .
Treatment failure is thought to be in part due to the short dwell-time of intravesical drugs and the low drug permeability of urothelium. Conventional formulations are typically maintained in the bladder for 2 h and urothelial drug exposure rarely lasts beyond the first voiding of urine after instillation (13) . Our approach to increase the dwell-time and uptake of intravesical drugs is to target the mucin glycoproteins on the surface of urothelium by exploiting the concept of mucoadhesion, which is an adhesive phenomenon occurring between certain type of polymers known as "mucoadhesive" polymers and the mucin-gel layer covering mucosal membranes.
The systems we are currently developing are based on hydrophobically derivatized hyperbranched polyglcerols (HPGs) which are dendritic-like macromolecules, with a hydrophobic core and a hydrophilic shell connected by covalent bonds in a single molecule (14) . The hydrophobic core is based on a mixture of alkyl (C 8 /C 10 ) chains which is important for the binding of hydrophobic molecules, including drugs, while the hydrophilic shell based on methoxy-poly(ethylene glycol) (MePEG, MW 350) keeps the system soluble in water (15) . In addition, HPGs possess many hydroxyl groups on the outer surface that can be further derivatized to increase their mucoadhesiveness.
Mucoadhesive systems possess numerous advantages when compared to conventional dosage forms. Localization at a specific region of the body helps improve drug uptake at the site of interest (16) . Mucoadhesion also increases the intimacy of contact between a drug-containing polymer and mucous surface, which can enhance the permeability of the drug (17) . Mucoadhesive polymers can also prolong residence time of the incorporated drugs, leading to less frequent dosing and improved patient compliance (18) .
Recently, we have reported the synthesis and characterization of HPG-C 8/10 -MePEG nanoparticles with surface derivatized amine groups (19) . The surface amine groups on HPG-C 8/10 -MePEG resulted in positively charged nanoparticles (HPG-C 8/10 -MePEG-NH 2 ) with improved mucoadhesive properties. We conducted a dose-range finding and tolerability study of intravesical docetaxel (DTX) in HPG formulations in an orthotopic model of bladder cancer and showed that intravesical DTX in either commercial or in HPG formulations (up to 1.0 mg/ml) was well tolerated with no apparent signs of toxicity in mice (19) .
The objective of the present work was to evaluate the effectiveness of intravesical mucoadhesive DTX loaded in HPG nanoparticles in an orthotopic model of bladder cancer and to investigate bladder tissue and tumor uptake of these nanoparticulate formulations.
Materials and Methods

Chemicals
All chemicals were purchased from Sigma-Aldrich (Oakville, ON) and all solvents were 
Cell lines
The human bladder cancer cell lines RT4 and UMUC3 were purchased from the American and these subclones were named KU7-luc as described previously (20) . The synthesis and characterization of HPG-C 8/10 -MePEG has been previously reported by our group (15) . Recently, we have described the surface derivatization of HPG-C 8/10 -MePEG with amine groups using N-(2,3-epoxypropyl)-phthalimide) (EPP) followed by cleavage of the phthalimide functional groups by hydrazinolysis (19) . The details on the synthesis and characterization of HPG-C 8/10 -MePEG and HPG-C 8/10 -MePEG-NH 2 have been provided in the Data Supplements section.
Rhodamine labeling of HPGs
HPG-C 8/10 -MePEG and HPG-C 8/10 -MePEG-NH 2 polymers were covalently labeled with tetramethyl-rhodamine-carbonyl-azide (TMRCA) as previously reported (21, 22) . Total run time was set to 5 min and DTX retention time was 2.9 min. Our HPLC method for quantification of DTX has been previously validated. This method was evaluated over a linear range of 0.5 -100 µg/ml. Over this range, the accuracy (percent deviation from theoretical value) was found to be within 3% and the precision (%RSD) was less than 2% using clean DTX standards. 
In vitro cytotoxicity studies
In vivo studies
Efficacy of intravesical DTX in orthotopic murine model of bladder cancer
The orthotopic mouse model used in the present study has been described in earlier publications (20, (23) (24) (25) (26) . Animal studies were carried out in accordance with the Canadian Drug uptake studies were conducted in fifteen-week-old female nude mice with established KU7-luc tumors (33 days post-tumor inoculation). Tail blood samples were taken at 0, 30, and 60 min post intravesical instillation. During this period mice were still anaesthetized with isoflurane. After 2 h, all mice were euthanized using CO 2 asphyxiation and additional blood was removed by cardiac puncture. Blood samples were centrifuged in micro-haematocrit tubes (Fisher Scientific, Pittsburg, PA) or serum-separator tubes (Becton Dicknson) and the serum was snap-frozen in liquid nitrogen. Urine and bladder of each mouse were also harvested and before freezing, the bladders were cut, opened to expose the lumen and were vigorously washed in five sequential 10 ml PBS washes. All samples were stored at -80 o C.
The UPLC-MS/MS system used for analysis consisted of an integrated Waters Acquity UPLC separation system (Acquity BEH C18, 1.7 µm, 2.1 X 50 mm column) coupled to a mass spectometry analysis using Waters TQD mass spectrometer. The system was operated at an electrospray ion source block temperature of 150°C, a desolvation temperature of Beckman-Coulter) for 15 min at 4°C. All sample analysis was performed using UPLC-MS/MS. The limit of quantification for DTX was 10 ng/ml with a recovery of 97% from spiked control samples. Within run precision (%RSD) was less than 15% in all cases.
Assessing tumor microenvironment and uptake of rhodamine labeled HPGs
Fifteen-week-old female nude mice with orthotopic bladder tumors (33 days post-tumor inoculation) were anaesthetized with isoflurane. A superficial 6/0 polypropylene purse-string suture was placed around the urethral meatus and the bladder was emptied by manual compression. A lubricated 24-gauge Jelco angiocatheter was passed through the urethra into the bladder and then 50 µl of either PBS, free rhodamine (TMRCA), HPG-C 8/10 -MePEG-TMRCA, and/or HPG-C 8/10 -MePEG-NH 2 -TMRCA was instilled and the purse-string suture was tied down for a 2-h period, during which the mice were kept anaesthetized. After the 2-h period the purse-string suture was removed, the bladder was emptied by manual compression and washed twice with 150 µl of PBS (pH 6.0). The mice were euthanized and the bladders were excised and frozen on an aluminum block, then embedded in OCT for cryosectioning. 
were dried at room temperature and imaged for rhodamine fluorescence using 10 x objective (0.75 µm/pixel resolution). Slides were fixed in 1:1 acetone : methanol solution for 10 min and stained using a custom capillary-action staining apparatus for CD31 (1:50 hamster anti-CD31 with an anti-hamster Alexa 647 secondary) and Hoechst 33342 (nuclear dye). HPGs were synthesized via anionic ring opening multibranching polymerization of glycidol using trimethylolpropane (TMP) as an initiator. The HPG core was derivatized with C 8 /C 10 alkyl chains to create a hydrophobic core, to allow the loading of DTX while the MePEG chains linked to hydroxyl groups on HPGs create a hydrophilic shell intended to increase the aqueous solubility of these molecules. To increase their mucoadhesiveness, amine groups were conjugated to some of the hydroxyl groups on HPG-C 8/10 -MePEG polymer in a two-step reaction procedure (Fig. S1, Data Supplements) . HPGs are small nanoparticles with hydrodynamic radii less than 10 nm. The surface modification of HPG-C 8/10 -MePEG with amine groups resulted in highly positive charged nanoparticles with improved mucoadhesive properties (Table S1, Data Supplements). DTX was loaded into these HPG nanoparticles due to hydrophobic interactions between the hydrophobic drug and the hydrophobic core of the HPGs. The maximum drug loading of DTX in HPGs was ~5%, which corresponded to about 5-6 DTX molecules per HPG molecule. Previously, we have shown that paclitaxel (PTX) can be loaded in HPGs, however the loading capacity was lower (2 vs 5% w/w) and this may be due to the fact that PTX is slightly larger (MW, 854 vs 808 Da) and more hydrophobic than DTX (22) . The release profiles of DTX from HPGs were characterized by a continuous controlled release with little or no burst phase of release.
Approximately 55% of initially encapsulated drug was released within the first 24 h of incubation in artificial urine. However, the presence of amine groups on the surface of HPGs had no effect on drug release (19) .
We evaluated the cytotoxic effects of the standard Taxotere 
proliferation in all cell lines tested. In agreement with our previous results with paclitaxel, the more aggressive and fast growing KU7-luc cell line was the most sensitive to DTX formulations (23, 24) . Loading of DTX in HPGs had no effect on its cytotoxicity. Indeed, DTX loaded HPG-C 8/10 -MePEG or HPG-C 8/10 -MePEG-NH 2 were found to be as cytotoxic as the commercial formulation of Taxotere ® (Fig. 1) .
Next, we evaluated the effectiveness of a single intravesical therapy with DTX formulations in a mouse xenograft model of bladder cancer. Orthotopic implantation of human cancer cells into immunodeficient mice is one of the best models currently available to assess the effects of intravesical anticancer therapy in vivo. Using both histologic evaluation and magnetic resonance imaging, our group has previously validated an orthotopic mouse model of bladder cancer in which luciferase expressing KU7-luc cells are transurethrally inoculated in nude mice and tumor burden is longitudinally quantified using bioluminescence imaging (20) . However, the fact that KU7 may not be of a human bladder origin has to be acknowledged, and our group is actively seeking new human urothelial carcinoma cell models for evaluation of intravesical therapy. The major issue with most human urothelial caricinoma cell lines is the low and non-reproducible tumor take in nude mice which makes intravesical evaluation challenging. Our objectives in this study, however, were not to develop nor to establish a 'true' non-muscle-invasive bladder cancer model but rather to evaluate the drug uptake and the efficacy of our newly developed mucoadhesive 
hoc Bonferoni analysis after 2-Way ANOVA). This increase in efficacy likely resulted from enhanced drug uptake in bladder and tumor tissues of mice treated with DTX loaded HPG-C 8/10 -MePEG-NH 2 nanoparticles. Our uptake studies have demonstrated significantly increased drug uptake in bladder tissues and enhanced tumor uptake of rhodamine labeled HPG-C 8/10 -MePEG-NH 2 nanoparticles (Table 1 & Fig. 4) . These results are in agreement with our recent studies in which DTX loaded HPG-C 8/10 -MePEG-NH 2 nanoparticles significantly increased the urinary bladder wall permeability and uptake of DTX in both isolated pig bladder as well as in a live mouse bladder tissues without tumors. Our preliminary studies on the effects of HPGs on the urothelium has demonstrated that HPG-C 8/10 -MePEG-NH 2 nanoparticles increase the permeability of the urinary bladder wall by causing changes to the urothelial barrier function and morphology through opening of tight junctions and exfoliation of the urothelium. These effects are similar to the effects on bladder mucosa caused by chitosan dispersions, a well-established, cationic, mucoadhesive polymer, which increased the permeability of isolated pig bladder to a model drug by causing desquamation of the urothelium (27) (28) (29) (30) .
Systemic absorption of chemotherapeutic drugs through the bladder wall is thought to be unlikely for agents with a molecular weight over 300 Da (31) . Thus, DTX (808 Da) theoretically has little risk of systemic uptake. However, similar to our previous studies with paclitaxel (854 Da) in healthy mice (24) , and in this model (23), we detected some systemic uptake especially in DTX loaded HPG-C 8/10 -MePEG-NH 2 treatment group. Systemic levels of DTX in the Taxotere ® group were below our limit of quantification which was 10 ng/ml. This may be due to DTX sequestration in micelles as has been reported for Taxol (Table 1) . Nevertheless, we did not observe any local or systemic toxicity in either group. Compared with humans, the mouse bladder wall is very thin and with an assumed logarithmic decrease in drug penetration across the tissue (33), lower serum levels would be expected in humans. In the recent phase I trial of intravesical DTX for the treatment of non-muscle-invasive bladder cancer refractory to BCG therapy, DTX was administered as in six weekly instillations with a dose-escalation up to 75 mg (34) . The authors reported minimal toxicity with dysuria being the most common; however, no systemic absorption was reported for intravesical DTX. BCG therapy is the most effective intravesical therapy to date; unfortunately, head-to-head comparison with our DTX formulations was not possible because our orthotopic murine model lacks an immune response, which is important for the effectiveness of BCG therapy. 
